MARKET

CAMP

CAMP

Camp4 Therapeutics Corp.
NASDAQ
4.200
-0.390
-8.50%
After Hours: 4.200 0 0.00% 16:04 03/06 EST
OPEN
4.470
PREV CLOSE
4.590
HIGH
4.565
LOW
4.060
VOLUME
36.21K
TURNOVER
--
52 WEEK HIGH
7.31
52 WEEK LOW
1.305
MARKET CAP
217.90M
P/E (TTM)
-1.6965
1D
5D
1M
3M
1Y
5Y
1D
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials
Seeking Alpha · 1d ago
Camp4 Therapeutics to Present at Stifel CNS Forum
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT) and Immuneering (IMRX)
TipRanks · 2d ago
CAMP4 to Participate in Upcoming Investor Conferences
Barchart · 2d ago
Leerink Partners Keeps Their Buy Rating on CAMP4 Therapeutics Corporation (CAMP)
TipRanks · 2d ago
William Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Cooper Co (COO) and CAMP4 Therapeutics Corporation (CAMP)
TipRanks · 2d ago
CAMP4 Therapeutics Corporation (CAMP) Receives a Buy from Piper Sandler
TipRanks · 2d ago
More
About CAMP
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.

Webull offers Camp4 Therapeutics Corp. stock information, including NASDAQ: CAMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CAMP stock methods without spending real money on the virtual paper trading platform.